Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Purchased by Acuitas Investments LLC

Acuitas Investments LLC raised its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 21.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 630,507 shares of the company’s stock after purchasing an additional 112,555 shares during the quarter. Acuitas Investments LLC’s holdings in Bolt Biotherapeutics were worth $473,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Assenagon Asset Management S.A. bought a new position in Bolt Biotherapeutics in the 2nd quarter worth approximately $26,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Price Performance

NASDAQ:BOLT opened at $0.65 on Friday. Bolt Biotherapeutics, Inc. has a 52-week low of $0.65 and a 52-week high of $1.56. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19. The firm has a market cap of $24.78 million, a P/E ratio of -0.39 and a beta of 0.94. The business’s 50-day moving average price is $0.71 and its 200 day moving average price is $0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative return on equity of 61.40% and a negative net margin of 592.57%. The business had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.19 million. As a group, sell-side analysts predict that Bolt Biotherapeutics, Inc. will post -1.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on BOLT shares. Leerink Partners reiterated a “market perform” rating and set a $1.00 price target (down previously from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday, August 15th. Stifel Nicolaus reissued a “hold” rating and set a $1.50 target price (down previously from $6.00) on shares of Bolt Biotherapeutics in a research note on Wednesday, May 15th. Guggenheim restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Finally, Leerink Partnrs cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 14th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bolt Biotherapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.